Physician profile
Mackenzie Pierce
NPI 1922726314
$822.35
in general payments reported to CMS, 2019-2025
16 companies · $783 in 2025
The $783 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $39.23 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $822.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $263.55 | 2025 | Reblozyl, Breyanzi |
| Abbvie INC. | $96.49 | 2025 | |
| Genmab U.S., INC. | $82.02 | 2025 | Epkinly |
| Daiichi Sankyo INC. | $79.74 | 2025 | Enhertu, Datroway, Vanflyta |
| Celgene Corporation | $42.00 | 2024-2025 | Reblozyl |
| Gilead Sciences, INC. | $31.26 | 2025 | Trodelvy |
| Array Biopharma INC | $27.42 | 2025 | Mektovi, Braftovi, Tukysa |
| Incyte Corporation | $26.31 | 2025 | Zynyz, Monjuvi |
| Tempus Ai, INC | $26.25 | 2025 | Xt Cdx |
| Kyowa Kirin, INC. | $25.46 | 2025 | |
| Genzyme Corporation | $24.66 | 2025 | |
| Genentech USA, INC. | $22.71 | 2025 | Itovebi |
| Sobi, INC | $19.75 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $19.26 | 2025 | Lynparza |
| Stemline Therapeutics INC. | $18.79 | 2025 | Orserdu |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $16.68 | 2024 | Myrisk |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.